Highest-materiality recent filing
Chemed Q2 2026: adj. EPS $6.06 (+41.9%), VITAS EBITDA +20.6%, guidance raised to $25.00-$25.75
Consolidated revenue $673.3M (+8.8% YoY); GAAP diluted EPS $5.13 (+43.7%); adjusted diluted EPS $6.06 (+41.9%).
Chemed say-on-pay fails at annual meeting; 61% votes against
Non-binding executive compensation proposal rejected: 4,383,683 For vs 6,926,656 Against (61.3% against).
Chemed Q1 adjusted EPS $5.65; boosts 2026 guidance to $24.00-$24.75 on VITAS momentum
GAAP diluted EPS $4.84, down 0.4% YoY; adjusted EPS $5.65, up 0.4% YoY.
Chemed renews $450M senior secured credit facility for five years
Five-year $450M revolving credit facility includes $100M letters of credit.
Chemed Q4 2025 GAAP EPS down 9%, Roto-Rooter segment weak; guidance for 2026 growth
Revenue $639.3M flat YoY; GAAP diluted EPS $5.48 (-9%), adjusted EPS $6.42 (-6%).
Chemed Q3 GAAP EPS falls 10.8% to $4.46; adjusted EPS down 6.6% to $5.27
Consolidated revenue $624.9M (+3.1% YoY); VITAS revenue $407.7M (+4.2%), Roto-Rooter $217.2M (+1.1%).
Chemed Q2 adjusted EPS $4.27 (-21.9% YoY); cuts FY2025 guidance; VITAS CEO departs
GAAP EPS $3.57 (-23.2%); adjusted EPS $4.27 (-21.9%); revenue $618.8M (+3.8%).
Chemed projects $18-25M Medicare Cap hit; lowers FY2025 guidance
VITAS expects $18M-$25M Medicare Cap revenue limit for Florida consolidated program (excl. Tallahassee) in 2025 Cap Year.
All nine director nominees elected; Kevin McNamara received 12,805,746 for vs 203,421 against.
Chemed Q1 revenue up 9.8% to $646.9M; GAAP EPS $4.86, adjusted $5.63
VITAS net revenue +15.1% to $407.4M; ADC 22,244 (+13.1%); adjusted EBITDA $70.3M (+15.9%).
Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45
GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).
GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).
Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80
Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).
All 10 director nominees elected; Kevin McNamara received 13.3M votes for, Patrick Grace 10.3M.
Chemed Q1 2024: Adjusted EPS $5.20 beats; VITAS EBITDA surges 67%, Roto-Rooter down 16%
Revenue +5.2% to $589.2M; GAAP EPS $4.24 (+18.4%); Adjusted EPS $5.20 (+21.5%)
VITAS completes $85M acquisition of Covenant hospice operations in Florida and Alabama
Purchased substantially all hospice operations and an assisted living facility from Covenant for $85M in cash.
VITAS to acquire Covenant Care hospice assets for $85M in cash
VITAS (Chemed subsidiary) agreed to purchase Covenant Care's hospice operations and an assisted living facility for $85M cash.
Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued
GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).
Chemed CFO David P. Williams transitions to CEO advisor role with new equity grant and salary
Williams resigned as EVP and CFO, now serves as advisor to CEO effective Jan 29, 2024.
Chemed appoints Michael Witzeman as CFO effective Jan 1, 2024, succeeding retiring David P. Williams
Michael Witzeman appointed CFO, effective January 1, 2024, replacing David P. Williams who is retiring.
Chemed CFO David P. Williams to retire Dec 31, 2023; will stay in transition role
Executive VP and CFO David P. Williams will retire effective December 31, 2023, after over 30 years at Chemed.
Chemed Q3 revenue +7.2% to $565M; raises FY2023 adjusted EPS guidance to $19.82-$20.02
GAAP diluted EPS $4.93 (+30.4% YoY); adjusted diluted EPS $5.32 (+24.9%).
Chemed Q2 revenue up 4.2% to $554M; adjusted EPS $4.71 down 2.7% YoY
GAAP diluted EPS $3.51; adjusted diluted EPS $4.71 (down 2.7% YoY).
Chemed shareholders re-elect all 10 directors, ratify PwC, approve executive compensation
All 10 director nominees elected; Patrick P. Grace and George J. Walsh III received ~3.3M and 2.1M against votes.
Chemed Q1 revenue up 5.6% to $560M; adjusted EPS $4.82 (+0.6%)
GAAP diluted EPS $3.58; adjusted diluted EPS $4.82, up 0.6% YoY.
Chemed Q4 2022 adjusted EPS $5.39 (+2.7% YoY); guides 2023 adjusted EPS $20.75-$21.10
Consolidated revenue $547M (+1.0% YoY); GAAP diluted EPS $4.13; adjusted diluted EPS $5.39.
Chemed amends bylaws to enhance stockholder proposal and director nomination procedures
Amendments require additional disclosures and representations regarding stockholder nominations and proposals.
Chemed appoints director John M. Mount, Jr. to Audit Committee
John M. Mount, Jr. appointed to Chemed Board effective August 5, 2022.
Chemed Q3 revenue down 2.3% to $526M; raises 2022 adjusted EPS guidance to $19.60-$19.70
GAAP diluted EPS of $3.78; adjusted diluted EPS of $4.74, down 6.3% YoY.
Director Donald E. Saunders retires; John M. Mount Jr. appointed to Chemed board
Donald E. Saunders retired from Chemed's Board effective 5:00 ET August 5, 2022.
Chemed Q2 adj EPS $4.84, raises FY22 guidance low-end to $19.30; Roto-Rooter revenue +6%
Revenue $531M, down 0.2% YoY; GAAP diluted EPS $4.40 (+25.4%); adjusted diluted EPS $4.84 (+5.2%).
Chemed enters $550M amended credit facility with $450M revolver and $100M term loan
Five-year $450M revolving credit facility and five-year $100M term loan.
Chemed shareholders elect all director nominees, approve 2022 stock incentive plan
All 10 director nominees elected; Joel F. Gemunder received 8.75M for, 3.92M against, 517k abstain.
Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%
Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).
Chemed Q4 2021 adj EPS $5.25, up 2.3%; VITAS revenue down 4.8%; issues mixed 2022 guidance
Consolidated Q4 revenue $541M (+1.4%); GAAP diluted EPS $4.81; adjusted diluted EPS $5.25 (+2.3%).
Chemed Q3 adj. EPS $5.06 (+4.1%), revenue $539M (+2%); FY21 guidance raised to $19.00-$19.20
Repurchased 350,000 shares for $164M; $148M remaining authorization; no long-term debt.
Consolidated revenue $532M (+6.0%); GAAP diluted EPS $3.51 (-29.9%); adjusted diluted EPS $4.60 (+4.3%).
To reflect his new role within the organization as an advisor to Chemed Corporation’s (the “Company’s”) Chief Executive Officer
On December 18 th , the Company’s Board of Directors appointed Michael Witzeman as the Company’s Chief Financial Officer, effective as of January 1, 2024.
On November 3, 2023, David P. Willaims advised Chemed Corporation (the “Company”) that he intends to retire effective December 31, 2023 as Executive Vice President and Chief Financial Officer of the Company.
On August 5, 2022, the Board of Directors (the “Board”) of Chemed Corporation (the “Corporation”) appointed John M. Mount, Jr. as a member of the Board.
Donald E. Saunders provided notice of his retirement from the Board of Directors of Chemed Corporation (the “Corporation”), effective as of 5:00 ET August 5, 2022.
On August 5 th , 2022, the Board of Directors of the Corporation appointed John M. Mount, Jr. to the Board, Mr. Mount is the North America Sports and Entertainment Marketing Team Lead at the Coca-Cola Company.
Max materiality 0.85 · Median 0.70 · Most common event earnings